MedTrace Logo

Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

NCT05295121 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-07-27

No results posted yet for this study

Summary

Primary objective of the study: evaluation of the effect of food intake on the bioavailability of XC221 100 mg tablets after a single oral administration in fed or fasted condition.

Additional objective of the study: evaluation of pharmacokinetic parameters, safety and tolerability of XC221 100 mg tablets in healthy volunteers after single oral administration in fed or fasted condition.

Conditions

  • Healthy

Interventions

DRUG

XC221 100 mg tablets

XC221, 3 discrete doses separated by 7-day wash-out periods

Sponsors & Collaborators

  • Valenta Pharm JSC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2022-02-22
Completion
2022-03-17

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05295121 on ClinicalTrials.gov